





ESI Manual of Clinical Endocrinology



Editors

**AC Ammini
Ambrish Mithal
Anil Bhansali
GR Sridhar
KM Prasanna Kumar
Nalini Shah
Nihal Thomas
Nikhil Tandon
Rakesh Sahay
RV Jayakumar
Sanjay Kalra
Shashank R Joshi
Subhankar Chowdhury**

Associate Editors

**Anurag R Lila
AG Unnikrishnan
Beena Bansal
Bindu Kulshreshta
Ganapathi Bantwal
Krishna G Seshadri
Manash P Baruah
Manoj Chadha
Parag Shah
Rajesh Khadgawat
Rama Walia
Sanjay Kumar Bhadada
SK Singh
Thomas V Paul
Tushar Bandgar**

Editor-in-Chief
Sarita Bajaj

2nd
Edition

Contents

Section 1: Diabetes and Metabolic Syndrome

Section Editors: GR Sridhar, Sanjay Kalra, Rakesh Sahay

Associate Editors: Manash P Baruah, Manoj Chadha, Krishna G Seshadri

1. The Diversity of Diabetes	3
<i>Sanjay Kalra, Vishal Gupta</i>	
2. Diabetes	6
<i>Rakesh Kumar Sahay, KD Modi, V Sri Nagesh</i>	
3. Type 1 and Type 2 Diabetes in Young	15
<i>AG Unnikrishnan</i>	
4. Type 1.5 Diabetes	20
<i>Sanjay Kalra, Tushar Bandgar</i>	
5. Gestational Diabetes Mellitus	25
<i>GR Sridhar, G Nagamani</i>	
6. Women's Health and Diabetes	32
<i>Usha Sriram</i>	
7a. Geriatric Diabetes	40
<i>Manash P Baruah</i>	
7b. Type 3 Diabetes Mellitus	48
<i>DC Sharma</i>	
8. Infections in Diabetes	52
<i>Arun S Menon, N Kotwal, Yashpal Singh</i>	
9. HIV and Diabetes	58
<i>Ranabir Salam, Sanjay Kalra</i>	
10. Malignancy and Diabetes	65
<i>Anurag R Lila, GR Sridhar</i>	
11. Nonpharmacological Management of Diabetes Mellitus	71
<i>Jubbin Jagan Jacob</i>	
12. Oral Antidiabetic Drugs	81
<i>Puneet Dhamija, Manoj Chadha</i>	
13. Incretin-Based Therapies	89
<i>Vageesh S Ayyar, Vivek Mathew</i>	
14a. Insulin Therapy: Pharmacology of Insulin	96
<i>Yashdeep Gupta, Manoj Chadha, Sanjay Kalra</i>	
14b. Premixed Insulin	101
<i>Sanjay Kalra, Ashok Kumar Das</i>	
14c. Basal Insulin	105
<i>SV Madhu</i>	
14d. Intensive Insulin Regimen	109
<i>Sarita Bajaj, Sameer Aggarwal</i>	

14e. Insulin and GLP1 RA Combinations	115
<i>Premlata K Varthakavi</i>	
14f. Smart Insulin and Future Developments	123
<i>Ameya S Joshi, Girish Parmar</i>	
15. Ethnopharmacy in Diabetes	129
<i>Mathew John, Sanjay Kalra</i>	
16. Glycemic Emergencies: Diabetic Ketoacidosis, Hyperosmolar Nonketotic Hyperglycemia, and Hypoglycemia	132
<i>Subhankar Chowdhury, Deep Dutta</i>	
17. Glycemic Control in ICU	141
<i>Sukhminder Jit Singh Bajwa, Sanjay Kalra</i>	
18. Hyperglycemia and Acute Coronary Syndrome	152
<i>MK Garg</i>	
19. Diabetes Education	158
<i>Rishi Shukla</i>	
20. Imaging of the Pancreas	161
<i>Vikas Chaudhary, Shahina Bano, Sanjay Kalra</i>	
21. Diabetes and Hypertension	172
<i>Mohan T Shenoy, Harish Kumar, Arun S Menon</i>	
22. Diabetes Mellitus and Lipids	177
<i>Mohan T Shenoy, Harish Kumar, Arun S Menon</i>	
23. Microvascular Complications in Diabetes	182
<i>Dinesh Kumar Dhanwal, Sanjay Pandit</i>	
24. Nonalcoholic Fatty Liver Disease and Diabetes	190
<i>Krishna G Seshadri</i>	
25. Musculoskeletal Effects of Diabetes Mellitus	199
<i>Sarita Bajaj, Rajiv Singla</i>	
26. Oral Complications of Diabetes Mellitus	206
<i>Shalu Bathla, Sanjay Kalra, Sarita Bajaj</i>	
27. Diabetes and Psychology	215
<i>Sanjay Kalra, Yatan Pal Singh Balhara, GR Sridhar</i>	
28. Diabetes and Psychiatry	221
<i>Yatan Pal Singh Balhara, Sanjay Kalra</i>	
29. Modern Biology and Diabetes	231
<i>Sadishkumar Kamalanathan C, GR Sridhar</i>	
30. Telemedicine in Diabetes Mellitus	242
<i>Ajay Sood, David C Aron</i>	
31a. Nontraditional Association of Insulin and Diabetes with Other Conditions	247
<i>GR Sridhar</i>	
31b. Vitamin D and Diabetes Emerging Links	253
<i>Rajat Gupta</i>	
31c. Testosterone and Diabetes Emerging Links	256
<i>Mohd Ashraf Ganie, Sobia Nisar, Mohd Shafi Kuchay</i>	
32. Foot Complications in Diabetes	261
<i>Jamal Ahmad, Mohammad Zubair</i>	

33. Metabolic Syndrome and the Gut Flora	277
<i>GR Sridhar</i>	
34. Sleep Circadian Rhythms and Diabetes	282
<i>Krishna G Seshadri</i>	
35. The HbA1c Assay: A Critical Appraisal	287
<i>Manash P Baruah, Bhaskar Bhattacharya</i>	
36. Online Risk Engines in Diabetes	292
<i>Partha Pratim Chakraborty, Sujoy Ghosh, Sanjay Kalra</i>	

Section 2: Thyroid

Section Editors: RV Jayakumar, Nikhil Tandon

Associate Editor: AG Unnikrishnan

37. Thyroid—Anatomy, Physiology, and Thyroid Function Tests	299
<i>RV Jayakumar, Praveen VP</i>	
38. Iodine Metabolism and Thyroid Disorder	308
<i>Chandrakant S Pandav, RK Marwaha</i>	
39. Hypothyroidism	311
<i>SK Singh, Sarita Bajaj, Vivek H Patel</i>	
40. Thyrotoxicosis	319
<i>Rakesh Kumar Sahay, Ganapathi Bantwal</i>	
41. Subclinical Thyroid Disorders	327
<i>Subhankar Chowdhury, Soumik Goswami</i>	
42. Euthyroid Goiter and Thyroid Nodules	334
<i>Nisha Bhavani, AG Unnikrishnan</i>	
43. Thyroiditis	340
<i>Bipin Sethi, GV Chanukya</i>	
44. Carcinoma of the Thyroid	345
<i>MV Muraleedharan, Arun S Menon</i>	
45. Thyroid Disease During Pregnancy	352
<i>Mala Dharmalingam</i>	
46. Thyroid Disorders in Children	364
<i>Meena P Desai, Vijayalakshmi Bhatia</i>	
47a. Special Situations in Thyroidology	379
PART A: Nonthyroid Diseases	379
<i>Premlata K Varthakavi</i>	
PART B: Thyroid Emergencies	383
<i>Nisha Bhavani</i>	
PART C: Thyroid Eye Disease	386
<i>Jubbin Jagan Jacob</i>	
47b. Drugs and Thyroid	395
<i>Sanjay Kalra, Suyog Subhash Jain, Manash P Baruah</i>	
47c. Thyroid and Bone	399
<i>Khalid J Farooqui, Dinesh Kumar Dhanwal, Ambrish Mithal</i>	

47d. Ultrasonography in Thyroid Diseases	403
<i>V Usha Menon, C J Sandhya</i>	
47e. Fine-Needle Aspiration Cytology in Thyroid Diseases	411
<i>Sandeep R Mathur</i>	
47f. Resistance to Thyroid Hormones	417
<i>Krishna G Seshadri</i>	
47g. Environmental Disruptors and Thyroid	422
<i>Madan M Godbole, Megha Chagtoo</i>	

Section 3: Pituitary

Section Editor: Nihal Thomas

Associate Editor: Thomas V Paul

48. Pituitary Function Tests	433
<i>D Rajitha, Alok Sachan</i>	
49. Disorders of Prolactin Excess	439
<i>Ganapathy Bantwal, Belinda George</i>	
50. Disorders of ACTH Excess	448
<i>Simon Rajaratnam, Kanakamani Jeyaraman</i>	
51. Disorders of Growth Hormone Excess	453
<i>V Suresh, Amaresh P Reddy</i>	
52. Nonfunctioning Sellar-Suprasellar Masses	461
<i>Sahana Shetty, Raghavendra Nayak, Thomas V Paul</i>	
53. Posterior Pituitary and Disorders of Water Homeostasis	470
<i>Vageesh S Ayyar</i>	
54. Hypopituitarism	482
<i>V Suresh, Amaresh P Reddy</i>	
55. Hypothalamus and Hypothalamic Disorders	490
<i>Nihal Thomas, Nitin Kapoor, Dukhabandhu Naik</i>	
56. Surgery for Pituitary Adenomas	496
<i>Ari George Chacko</i>	
57. Pituitary Incidentalomas	504
<i>Nihal Thomas, Dukhabandhu Naik, Ari George Chacko</i>	
58. Imaging of Pituitary	513
<i>Sunithi E Mani, Aparna Irodi, Sniya Valsa Sudhakar, Simon Rajaratnam</i>	
59. Radiotherapy of the Pituitary	538
<i>Subhashini John</i>	
60. Multiple Endocrine Neoplasia Type 1	546
<i>HS Asha, Thomas V Paul, Nihal Thomas</i>	

Section 4: Adrenals

Section Editor: Anil Bhansali

Associate Editors: Ganapathi Bantwal, Rama Walia

61. Adrenal Gland: Anatomy and Physiology	561
<i>Rajesh Rajput</i>	

62a. Cushing Syndrome: Symptomatology and Diagnostic Strategies	565
<i>Rajesh Rajput</i>	
62b. Treatment and Follow-Up Strategies in Cushing's Syndrome	569
<i>Anurag R Lila, Tushar Bandgar</i>	
63. Primary Adrenal Insufficiency	573
<i>Yashpal Gogate, Anil Bhansali</i>	
64. Management of Adults with Congenital Adrenal Hyperplasia	578
<i>Nalini Shah, Sweta Budyal</i>	
65. Pheochromocytoma—Molecular Genetics, Diagnosis, and Treatment Strategies	585
<i>Simon Rajaratnam, Rekha Pai</i>	
66. Primary Aldosteronism	592
<i>Prathosh Gangadhar, Anil Bhansali</i>	
67. Adrenocortical Carcinoma Current Concept and Treatment Strategies	600
<i>Rama Walia</i>	

Section 5: Bone and Mineral Disorders

Section Editor: *Ambrish Mithal*

Associate Editors: *Sanjay Kumar Bhadada, Beena Bansal*

68. Basics of Bone Physiology	607
<i>Vupputuri Madhava Rao, Nikhil Tandon</i>	
69. Basics of Mineral Physiology	613
<i>Monashis Sahu, Ambrish Mithal</i>	
70. Primary Hyperparathyroidism: An Indian Perspective	620
<i>Sanjay Kumar Bhadada, Ambrish Mithal</i>	
71. Hypoparathyroidism–Hypocalcemia	629
<i>Sagar Modi, Ravinder Goswami</i>	
72a. Vitamin D Status of Indian Population	635
<i>RK Marwaha, Ambrish Mithal, CV Harinarayan</i>	
72b. Vitamin D Toxicity	639
<i>Parjeet Kaur, Sunil Kumar Mishra, Ambrish Mithal</i>	
73a. Epidemiology and Risk Factors of Osteoporosis	643
<i>Dinesh Kumar Dhanwal, Beena Bansal</i>	
73b. Diagnosis of Osteoporosis and Assessment of Fracture Risk	647
<i>Beena Bansal</i>	
73c. Treatment of Osteoporosis	652
<i>Ambrish Mithal, Beena Bansal</i>	
74. Metabolic Bone Disease in Children	658
<i>Ganesh Jevalikar, Rajesh Khadgawat</i>	
75. Medical Evaluation of Nephrolithiasis	667
<i>Sushil Kumar Gupta, Sanjay Kumar Bhadada</i>	
76. Fluorosis	678
<i>CV Harinarayan</i>	

Section 6: Reproductive Endocrinology

Section Editors: AC Ammini, KM Prasanna Kumar

Associate Editor: Bindu Kulshreshta

77. Evaluation of Amenorrhea	685
<i>Puliangudi Gokulakrishnan Sundararaman</i>	
78. Management of Hypogonadism in Females	695
<i>Rajagopalan Muralidharan</i>	
79. Polycystic Ovary Syndrome	706
<i>Mohd Ashraf Ganie, Syed Douhath, KK Pandita, Mohd Shafi Kuchay</i>	
80. Hyperandrogenism Other than PCOS	717
<i>Pramila Kalra</i>	
81. Primary Ovarian Failure and Menopause	730
<i>Rajiv Singla, Viveka P Jyotsna</i>	
82. Female Hormonal Contraception	737
<i>Garima Kachhawa, Rajesh Khadgawat</i>	
83. Gynecomastia	743
<i>MV Muraleedharan</i>	
84. Male Reproductive System: Clinical Examination and Investigations	746
<i>Sunil M Jain</i>	
85. Treatment of Hypogonadism in Males	753
<i>Sudip Chatterjee</i>	
86. Andropause and Adult Onset Male Hypogonadism	757
<i>Shashank R Joshi</i>	
87. Erectile Dysfunction	762
<i>Mohd Ashraf Ganie, Khalid J Farooqui, KK Pandita</i>	
88. Male Contraception	768
<i>Abhay Gundgurthi, KM Prasanna Kumar</i>	

Section 7: Pediatric Endocrinology

Section Editor: Nalini Shah

Associate Editors: Rajesh Khadgawat, Tushar Bandgar, Anurag R Lila

89a. Growth Hormone Disorder: Approach to Short Stature	777
<i>Shrikrishna V Acharya, Raju Gopal</i>	
89b. Use of Growth Hormone in Non-GHD Conditions	783
<i>Mathew John</i>	
89c. Growth Hormone Deficiency in Children	790
<i>Rajni Sharma, Anju Seth</i>	
90a. Delayed Puberty	797
<i>Premalata K Varthakavi, Nikhil M Bhagwat, Ameya S Joshi</i>	
90b. Precocious Puberty	806
<i>SK Singh, Naresh Bansal</i>	
90c. Turner Syndrome	814
<i>Anurag Bajpai</i>	

91a. 46,XX Disorders of Sexual Development	821
<i>Shivaprasad C</i>	
91b. 46,XY Disorders of Sexual Development	829
<i>Shivaprasad C</i>	
92. Type 1 Diabetes (Pediatric Endocrinology)	837
<i>Subhankar Chowdhury, Ankit Shrivastav</i>	
93. Metabolic Syndrome in Children and Adolescents	845
<i>Amaresh P Reddy, Alok Sachan</i>	
94. Rickets	853
<i>Rama Walia</i>	
95a. Neonatal Screening for Endocrine Disorders	859
<i>Vijaya Sarathi</i>	
95b. Neonatal Endocrine Emergencies	862
<i>Praveen VP, Ajish TP</i>	

Section 8: Obesity

Section Editors: Subhankar Chowdhury, Shashank R Joshi

Associate Editors: SK Singh, Parag Shah

96. Obesity Global and Indian Overview	877
<i>Rajesh Rajput</i>	
97. Adipose Cell Biology	881
<i>Uday Phadke</i>	
98. Changing Human Architecture and Energy Equations in Obesity	889
<i>Shashank R Joshi, Shilpa Joshi</i>	
99. Etiopathogenesis of Obesity Including Secondary Causes: Both Endocrine and Genetic Syndromes	897
<i>Soumik Goswami, Subhankar Chowdhury</i>	
100. Approach to an Obese Patient—Protocols and Plans	904
<i>Deep Dutta, Sujoy Ghosh, Subhankar Chowdhury</i>	
101. Management of Obese Patient—Behavior, Diet, Activity and Treatments	913
<i>Shashank R Joshi, Shilpa Joshi</i>	
102. Bioactives in Obesity	918
<i>Shilpa Joshi, Shashank R Joshi</i>	
103. Preventive Strategies in Obesity	923
<i>Soumik Goswami, Subhankar Chowdhury</i>	
<i>Index</i>	929

Chapter

4

Type 1.5 Diabetes

Sanjay Kalra, Tushar Bandgar

■ DEFINITION AND EPIDEMIOLOGY

Diabetes mellitus is a vast syndrome encompassing a diverse range of clinical conditions. The current classifications of diabetes, such as those published by the American Diabetes Association (ADA), acknowledge this diversity. While the majority of cases can be termed as type 1 or type 2 diabetes, some patients challenge conventional terminology. While the ADA mentions type 1, type 2, and gestational diabetes mellitus, it also lists at least 48 other specific types of diabetes.

The exhaustive classifications of diabetes that are in use do not mention the term “type 1.5 diabetes”. Yet all endocrinologists will agree that there are a sizeable number of patients with diabetes, who do not fit into the watertight compartments of type 1 or type 2 diabetes. This chapter covers two subgroups of such patients, who may be termed as having type 1.5 diabetes.

The American Diabetes Association classifies diabetes as being type 1 or type 2 based on the insulin deficiency conceivably manifested by the presence of diabetic ketoacidosis (DKA). All patients who present with DKA are considered to have type 1 diabetes, and out of them, those who are negative for autoantibodies are termed “idiopathic type I” or “type Ib”. American Diabetes Association scheme would classify both type 1a and 1b diabetes as insulin-dependent diabetes. Although ADA 2014 acknowledges that some patients cannot be clearly classified into type 1 or type 2 diabetes, it does not specifically address the group of patients who present with DKA, and later achieve control with oral drugs or lifestyle measures. These patients may be termed as having type 1.5 diabetes, as they initially behave as type 1 (ketosis prone), converting later into type 2 diabetes.

A diametrically different clinical picture is seen in patients with autoimmune diabetes (ADA classification type 1) who do not present with ketosis, including those termed “Latent Autoimmune Diabetes in Adults” (LADA), and “slowly progressing type 1 diabetes”. This, too, is termed as type 1.5 diabetes.

Investigators at Emory University, Atlanta, have studied ketosis-prone diabetic (KPD) patients, and separated them into lean or obese. The ketosis-prone patients who are lean and resemble clinically type 1 diabetic patients with lower β -cells functional reserve are termed as “lean Ketosis-prone diabetic” and those who are obese and having clinical features as that of type 2 diabetes with some preserved functional β -cells are termed as “obese ketosis-prone diabetic”.

The lean patients may achieve initial, short term control with oral drugs, but progress soon to insulin dependence. These too, may be termed as type 1.5 diabetes.

At the University of Paris, KPD patients were placed into three groups as follows:

1. “type Ia” for patients with positive autoantibodies, same as that classified by ADA
2. “KPD ID” for the patients who are negative for autoantibodies and are documented to have long-term insulin dependence
3. “KPD-NID” for the patients who are negative for autoantibodies and are documented to have long-term insulin independence.

Clinical features of both “Type Ia” and “Insulin dependent KPD” are similar to the patients with type I diabetes mellitus with poor β -cell function, whereas clinical features of “noninsulin dependent KPD” patients are similar to that of type 2 diabetes mellitus with preserved β -cell function over a prolonged duration (Box. 4.1).

Box 4.1: A- β Classification by Baylor College of Medicine & University of Washington.

<i>Class</i>	<i>Autoantibodies</i>	<i>Functional β cell reserve</i>
A+ β -	Positive	Absent
A+ β +	Positive	Present
A- β -	Negative	Absent
A- β +	Negative	Present

There is, thus, a spectrum of clinical phenotypes and genotypes among patients with diabetes who present with certain type 1 and other type 2 features.

In Western literature, type 1.5 diabetes is usually taken to mean LADA. The definition of LADA has recently been standardized. It excludes patients who require insulin within the first 6 months after diagnosis.

In India, the term type 1.5 diabetes is used at times to refer to the KPD that later responds to oral drugs. The authors propose the term ketosis-prone type 2 diabetes (KPD2) for this distinct subgroup of diabetic patients that has a different natural history and management.

ETIOPATHOGENESIS

Latent autoimmune diabetes in adults is characterized by presence of one or more antibodies to glutamic acid decarboxylase (GAD), islet cell antibody, or insulin autoantibodies (IAA).

Latent autoimmune diabetes in adults is further classified as LADA type 1 and type 2. Latent autoimmune diabetes in adults type 1 has two or more antibodies present, in high titers, with a phenotype closer to that of classic type 1 diabetes. Latent autoimmune diabetes in adults type 2 has the phenotypic characteristics of type 2 diabetes, with low titers of only one antibody being detected.

Ketosis-prone type 2 diabetes is also characterized by the presence of antibodies in some patients. The phenotype is similar to that of type 2 diabetes.

CLINICAL FEATURES

Studies have been reported from various parts of India on the presence of these atypical type 1.5 diabetes syndromes.

Rothangpui, et al. (2011) from Imphal, Manipur, report of lean type 2 diabetes, with a high prevalence of secondary oral hypoglycemic failure. These patients have high incidence of microvascular, but low incidence of macrovascular complications.

Kalra S, et al. (2009) from Karnal, Haryana, report the existence of KPD2 in the endocrine outdoor patient department (OPD). These patients need high doses of insulin to begin with, but achieve good control with oral drugs later on. These KPD2 are dark, hirsute, obese patients, with a male preponderance, with stigmata of insulin resistance such as acanthosis nigricans. Balanoposthitis and pruritus vulvae are frequent presenting symptoms. In contrast, LADA patients in this part of the country have a phenotype that is lean, with fair complexion, light colored hair and eyes, hairless body skin, and stigmata of autoimmune illness such as goiter, arthritis, and arthralgia.

Ashida TS (2007), from Pondicherry, studied the feasibility of using phenotypic markers and serum insulin estimations in classifying type of diabetes in 60 early onset type 2 diabetic patients in the age group 25–40 years and 60 patients in a row with type 2 diabetes aged 50 and above. Measurement of serum insulin was done using Radio Immuno Assay Kit from Bhabha Atomic Research Centre.

Based on fasting insulin levels, they classified early onset group into those with (46 patients) and those without fasting hyperinsulinemia (14 patients).

They observed significant differences among the two groups. Nonhyperinsulinemic group showed earlier age of onset, with 39.1% having explosive onset, and none being obese whereas hyperinsulinemic group showed insidious onset at a later age, and two-thirds of them were obese. A total of 10.80% patients of nonhyperinsulinemic group and 92.85% in hyperinsulinemic group had no family history of diabetes, while rest of the patients had one or more members having diabetes. Twenty patients (43.47%) with single diabetic parent, eight patients (17.39%) with both the parents diabetic while 12 patients (26.08%) with diabetic siblings marked the hyperinsulinemic group, with one patient having positive family history in three generations suggestive of an autosomal dominant mode of inheritance. However, in nonhyperinsulinemic group, only one patient gave positive family history of diabetes.

Hyperinsulinemic group showed higher prevalence of microvascular complications, though it was statistically insignificant as compared to the other group. Among both groups, all patients responded to initial oral hypoglycemic agents (OHAs) with good glycemic control, but 11% of nonhyperinsulinemic group ultimately required insulin.

The subgroup of patients that was noted to be nonobese had explosive onset of diabetes, infrequent family history

Table 4.1: Antibodies in diabetes.

<i>Antibodies</i>	<i>Prevalence in type 1 diabetes mellitus</i>	<i>Prevalence in type 2 diabetes mellitus</i>	<i>Prevalence in general population</i>	<i>Method of testing</i>
Antiglutamic acid decarboxylase decarboxylase	5–83.3%	Adult: 12% Child: 21% GDM: 5–18%	1.5%	Fluid-phase 125 I-antigen binding assays by the use of recombinant human GAD65, ELISA
Islet cell antibodies (ICA)	85%	Adult: 12% Child: 33% GDM: 5–18%	0.95%	Indirect immunofluorescence
Insulin autoantibodies	50–70%, better in children than in adults	30–40%	0.36%	Competitive fluid-phase antigen-binding assay using A14 mono-125 I-insulin
Antibody against the protein tyrosine phosphatase (PTP)-like protein known as ICA-512 (IA-2)	60–70%	10–14%	0.91%	Fluid-phase 125 I-antigen binding assays by the use of recombinant human IA-2ic, ELISA

(GDM: Gestational diabetes mellitus; ELISA: Enzyme-linked immunosorbent assay).

of diabetes, absence of fasting hyperinsulinemia, low prevalence of complications at diagnosis, poor response to OHA, and higher chance of insulin requirement and possibly had LADA.

MODALITIES OF DIAGNOSIS

While diabetes is diagnosed by routine investigations, LADA can be diagnosed early, using antibody estimations, and later by a retrospective review of clinical history. The various antibodies that are useful in the differential diagnosis of type 1.5 diabetes are listed in Table 4.1.

Presence or absence of β -cell antibodies with special emphasis on their titers along with β -cell function reserve tests helps the physicians to assess and predict patient's clinical course. Glutamic acid decarboxylase65 (GAD65) and insulin autoantibodies-2 (IA-2) autoantibodies measured with highly sensitive and specific assays are useful and their titers should be considered as positive if antibody index exceeds ethnic-specific 99th percentile. There is a need for India-specific cutoffs for various pancreatic autoantibodies.

Human leucocyte antigen (HLA) testing for type 1 susceptibility alleles such as HLA DQB1*02 can be done in antibody-positive patients to predict risk of β -cell function deterioration. Patients who have been treated with exogenous insulin in the past; antiinsulin antibodies are not helpful.

Ketosis-prone type 2 diabetes can be suspected on clinical presentation, and by antibody measurement, but

the diagnosis can be confirmed only once insulin independence is achieved. The differentiating points on historical review, clinical examination, and investigation are listed in Table 4.2.

TREATMENT

Clinical management of type 1.5 includes initial management, the management during transition phase, and long-term management.

In LADA, initial management may be with oral hypoglycemics, though control will not last for long. Patients need to be motivated and counseled for insulin that should be started as soon as possible. In the Indian setting, premixed insulin is the drug of choice. Incretin-based therapies have not been studied in LADA.

In KPD2, initial management of ketosis will depend on the severity of metabolic decompensation. Initial correction of dehydration by fluid replacement along with continuous insulin administration, evaluation for underlying cause and its treatment, continuous monitoring for resolution of KA, hyperglycemia along with electrolyte correction, and transition to subcutaneous insulin regime from intravenous forms the basis of treatment strategy. Some patients with ketonuria (moderate or less) without acidosis may be managed on an outdoor patient basis.

β -cell function evaluation and autoantibodies against it should be evaluated after 1–3 weeks of complete recovery from DKA so as to avoid acute effects of glucotoxicity and β -cell desensitization.

Table 4.2: LADA versus KPD2 versus secondary OHA failure.

	<i>LADA</i>	<i>KPD2</i>	<i>Secondary OHA failure</i>
Age of onset	Young adults	Young adults	Middle aged adults
Gender	M = F	M > F	M = F
Presentation	Insidious	Explosive	Insidious
Body weight	Lean	Obese	Variable
Ketosis	Uncommon	At onset	Uncommon
Antibodies	Strongly +ve	+ve	-ve
Initial management	OHA	Insulin	OHA
Long-term management	Insulin	OHA	Insulin

(LADA: Latent autoimmune diabetes in adults; KPD2: Ketosis-prone type 2 diabetes).

Serum C peptide (Cpep) concentration both fasting and glucagon stimulated should be done to predict β -cell secretory function at 6 months as well as to predict glycaemic control after 1 year. Ketosis prone diabetic patients with higher Cpep levels have higher insulin discontinuation rates.

C peptide can be used to classify the type of diabetes. C peptide consists of a small molecule that may suffer cleavage from proteolytic enzymes and, therefore, the plasma must be separated within 2 hours of venipuncture. There is controversy regarding the ideal method and utility of Cpep measurement. Some of this concerns the glycaemic homeostasis conditions under which Cpep must be measured. Hyperglycemia may increase (by direct stimulation of glycemia) or decrease (by glucotoxicity) the β -cell response to the test, as well as hypoglycemia may inhibit the β -cell response. For that reason, Cpep measure must be made in the absence of hyper- or hypoglycemia, as the ideal glycemia would be between 70 and 200 mg/dL. C peptide measure may be made in the basal or stimulated by endovenous, intramuscular, or subcutaneous glucagon, oral or endovenous amino acids, oral or endovenous glucose, and by mix diet. The two most used stimulations are androgenous glucagon and the mixed diet test, as the latter is strongly recommended by ADA.

The patient is characterized with type 1 diabetes mellitus when he/she presents Cpep values <1.8 ng/dL after 1 mg of endogenous glucagon, and below 1.5 ng/dL after a mixed meal. Some authors suggest that the basal value alone would be sufficient to characterize the patient, and a study has shown that the random Cpep value (1.5 ng/mL cut-point) measured at any time would be more sensitive. A classical Danish study indicated that a basal value inferior to 0.9 ng/mL could already be able to indicate insulin dependence.

Future insulin independence can be predicted if insulin requirements fall rapidly. The first clinic visit is within 1–2 weeks of discharge from the hospital. Subsequent visits are scheduled at 1–4-week intervals as indicated. Doses of insulin are titrated according to glucose values. Metformin is started in KPD2 patients at about 2 weeks after resolution of ketosis. Sulfonylureas or incretin-based therapy may be added, if required, a few weeks later, as insulin requirements drop. Insulin is usually discontinued within 6–12 weeks of the initial episode of ketosis.

Regular self monitoring of blood glucose (SMBG) monitoring for glycaemic control is advisable along with urine ketones or blood ketones testing with strips to check ketosis if blood glucose >200 mg/dL.

Lifestyle interventions are continued if glycaemic goals are reached and can be tried without pharmacological treatment but with close SMBG monitoring. If glycaemic goals are not met, then oral hypoglycaemic agents need to be started. And if upon decreasing insulin dose, ketosis develops, then insulin should be intensified and later should not be discontinued.

Patients should be counseled regarding the nature of their disorder, and the fact that it is different from that of other diabetes patients.

PROGNOSIS

Latent autoimmune diabetes in adult patients will eventually need insulin, and once the diagnosis is established, no attempt should be made to withdraw insulin. Though they may not go into ketosis, glycaemic control will not be achieved with oral hypoglycemics.

Occurrence of DKA in KPD patients can classify them into two groups, viz., one with DKA at initial presentation and the other group with development of DKA due to

significant stress in already diagnosed diabetics. Those with DKA as initial presentation have better prognosis with higher insulin discontinuation rates and good control of glycemia. In $\beta+$ patients, multiple factors like new onset diabetes with later onset and higher β -cell secretory function reserve, viz., fasting C peptide:glucose ratio > 11 help in better prediction for insulin discontinuation.

Although antibody-positive KPD patients have low β -cell reserve both soon after resolution of acute acidosis and also during later long-term follow-up period, most of them can discontinue insulin initially with close monitoring. HLA testing in antibody-positive KPD patients for specific type 1 diabetes susceptibility alleles can be useful to predict earlier deterioration with earlier insulin dependence (within 1–2 years) and also to identify candidates for immunomodulatory therapy in future (type 1.5 diabetes).

CONCLUSION

The prevalence of atypical forms of diabetes, which may be termed as type 1.5 diabetes, is not insignificant. While it is not feasible to assess antibodies in all patients in a resource challenged setting, careful observation of features on history and examination, coupled with simple investigations, can help distinguish these forms of diabetes.

Early recognition of LADA and KPD2 avoids misunderstanding on part of patients, relatives and health care

professionals. It can help in timely institution of appropriate therapy, as well as optimal patient counseling. This, in turn, will help prevent the various complications associated with poor glycemic control.

SUGGESTED READING

1. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. *Scand J Clin Lab Invest.* 2000; 60:687-93.
2. Bingley PJ. Clinical applications of diabetes antibody testing. *J Clin Endocrinol Metab.* 2010;95:25-33.
3. Kalra S, Kalra B, Sharma A. Ketouria and ketonemia in type 2 diabetes mellitus patients attending an Indian endocrine clinic. *Indian J Endocrinol Metab.* 2007;11.
4. Knip M. Can we predict type 1 diabetes in the general population? *Diabetes Care.* 2002 Mar;25(3):623-5.
5. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: a distinct but heterogeneous clinical entity. *World J Diabetes.* 2010 Sept 15;1(4):111-5.
6. Reinehr T, Schober E, Wiegand S, et al. On behalf of the DPV-Wiss Study Group b-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? *Arch Dis Child.* 2006;91:473-7.
7. Rothangpui, Singh SD, Singh P, et al. Diabetic cardiomyopathy in Manipur. *Indian J Endocrinol Metab.* 2011;15: 204-08.
8. Sjoberg S, Gunnarsson R, Ostman J. Residual C-peptide production in type I diabetes mellitus: a comparison of different methods of assessment and influence on glucose control. *Acta Med Scand.* 1983;214:231-7.

ESI Manual of Clinical Endocrinology

Hormones being everywhere are indirectly or directly involved in all diseases. The ESI Manual of Clinical Endocrinology covering all major subspecialties and assimilating the most current knowledge and evidence-based clinical approaches is a clinic friendly-ready reference that has enormous value to all healthcare professionals confronted with endocrine problems.

A quick introduction to the newcomer it helps to update knowledge in diagnosis and therapeutic strategies, not having to wade through extremely rare conditions or tests and treatments. The book gives an Indian perspective of Endocrinology, focusing mainly on those endocrine disorders which are more common in our country, incorporating as much Indian Data as is available. Novel chapters, including those on the diversity of diabetes, ethnopharmacy, womens' health and oral complications, adrenal insufficiency, environmental disruptors, drug nuances and thyroid, hypopituitarism, andropause, Vitamin D status in India and neonatal endocrinology make this volume stand out amongst existing texts. This edition is endowed with an entirely new section devoted to obesity.

This book should be of great interest to endocrinologists, internists and family practitioners who care for patients with endocrine problems.

Sarita Bajaj MD (Med) DM (Endo) currently Director-Professor and Head Internal Medicine, MLN Medical College, Allahabad, Uttar Pradesh, India is a pioneer in the field of Endocrinology. Her major contribution is towards studies on Diabetes, Obesity and Growth. She has almost 100 publications in peer reviewed journals, monographs and books. She has been awarded WHO Fellowship in Endocrinology to visit SIU School of Medicine, Springfield, Illinois, USA and fellowship of the State Diabetes Association. She is holding and has held many important posts viz: President South Asian Federation of Endocrine Societies, President Women in Endocrinology & Diabetes, President Endocrine Society of India, Vice-President Research Society for the Study of Diabetes in India, Vice-President State Endocrine Society, President State Diabetes Association, Vice-President Diabetes India and Executive member Indian Thyroid Society. She was the Syllabus Chair for the International Clinical Update in Endocrinology, 2014 and is the Scientific Chair for Research Society for the Study of Diabetes in India, 2015.



Dr Sarita Bajaj lectures extensively throughout the country and has been awarded several prestigious orations. Education is her forte and passion—for medical professionals and public. Honours have bestowed upon her in the scientific and public field for her yeomen contribution to the medical fraternity and society in endocrine education and awareness.

Available at all medical bookstores
or buy online at www.jaypeebrothers.com



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation
ENDOCRINOLOGY

